top of page

A New Path Forward for Treatment-Resistant Depression 

When Standard Antidepressants Aren't Enough​

SPRAVATO® (esketamine) at Mercury Mental Health​

SPRAVATO® is an FDA-approved prescription medication administered under medical supervision for adults with treatment-resistant major depressive disorder. If you've tried antidepressants but continue to struggle with depression, SPRAVATO® may offer a different path forward.

Insurance coverage is common, and our team will help determine eligibility and obtain prior authorization when needed.​

How to start

  1. Book now with Sam Parmenter​

  2. Insurance benefit verification 

  3. Initial evaluation appointment 

  4. Prior authorization for Spravato, if approved and appropriate, we’ll schedule your first treatment session.

  5. Month One: 2 treatment sessions weekly

  6. Month Two: 1 treatment session weekly

  7. Maintenance: treatment sessions occur weekly or every 2 weeks for those who receive benefit

Questions? Please email us at: hello@mercurymentalhealth.com

Disclaimer: This page is informational and not medical advice. Final eligibility and scheduling follow clinical evaluation and payer requirements.

This treatment may be a good fit for:

  • Adults with treatment-resistant depression: Those who have not experienced adequate improvement after trying at least two antidepressants.

  • Those struggling with traditional antidepressants: People who continue to experience significant depressive symptoms despite treatment, including those who have also struggled with side effects such as weight gain, sexual dysfunction, or emotional blunting.

  • Those seeking faster relief from depression: Unlike traditional antidepressants, which often take weeks to work, SPRAVATO may begin improving depressive symptoms within hours to days for some patients.

SPRAVATO is FDA-approved for treatment-resistant major depressive disorder in adults. It is not currently FDA-approved for bipolar depression.Eligibility will be determined during your initial appointment.

What to expect at your Spravato in-office visit

  • Brief check-in and vitals → self-administer SPRAVATO® under supervision → quiet recovery with monitoring for 2 hours in a comfortable recliner with optional eye mask, blanket, and gentle music.

  • Please plan to arrange for a ride home.

Adverse effects

Most side effects from Spravato occur during or shortly after treatment (such as dissociation, sedation, dizziness, nausea, respiratory depression, and temporary increases in blood pressure), which is why patients are monitored in-office for at least two hours. For most patients, side effects are temporary and resolve the same day. Long-term or persistent side effects are uncommon, and we monitor for safety throughout treatment.

IMG_4623.heic

The 
Threatment Space
 

IMG_4498 2.HEIC

For clinicians & referral partners

We accept referrals for SPRAVATO® only—you keep primary medication management.

  • We manage Spravato treatment while patients continue care with their primary psychiatric provider

  • With an ROI, we provide regular updates on response and safety

  • Refer/coordinate: hello@mercurymentalhealth.com | Fax (812) 407-2467

Mark’s Journey With SPRAVATO® (esketamine) Nasal Spray | Real TRD Patient Story
15:39
Allison: A SPRAVATO® (esketamine) Success Story
16:19
Karen: A SPRAVATO® (esketamine) Nasal Spray Success Story
14:19
Amy's Success Story: SPRAVATO® (esketamine) Nasal Spray
13:34
Grace: SPRAVATO® (esketamine) Success Story | SPRAVATO® (esketamine)
16:14
Ben: A SPRAVATO® (esketamine) Nasal Spray Success Story
13:32
Nicole: SPRAVATO® (esketamine) Success Story | SPRAVATO® (esketamine)
14:18
Sally: A SPRAVATO® (esketamine) Success Story | SPRAVATO® (esketamine)
13:40
Mercury Mental Health Logo

©2022 by Mercury Mental Health

Privacy Policy

bottom of page